Patient P-02051
Therapy response
Stable
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
59%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −26% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 74 GI-04 recommended — GI Support Protocol GI-04
- Day 74 SC-12 recommended — Supportive Compound SC-12
- Day 75 Patient accepted — Started GI-04 in the companion
- Day 75 Patient declined — Not now
- Day 83 GI symptom burden −31% vs expected — GI Support Protocol GI-04
- Day 85 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 88 ME-01 recommended — Monitoring Escalation ME-01
- Day 89 Tolerance state changed — Unstable → Improving
- Day 89 Patient accepted — Started ME-01 in the companion
- Day 92 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 85.
Primary contributors, last 14 days
- GI instability-10
- Inflammatory activity-7
- Treatment adherence+5
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −26%
- GI Support Protocol GI-04Day 74Result: symptom burden −31%
- Supportive Compound SC-12Day 74Declined by patient
- Monitoring Escalation ME-01Day 88Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
54%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 48
- Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 46
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 3.2 · butyrate capacity 47/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 57 ms
- Sleep
- 6.4 h
- Steps
- 5,618
- Resting HR
- 64 bpm
Daily log: GI score 40, nutritional resilience 46, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02093 | 24% | S05 | AD-05 | no change | 40 |
| P-02483 | 27% | S06 | BR-03 | no change | 64 |
| P-02087 | 24% | S01 | BR-03 | no change | 40 |
| P-02522 | 24% | S01 | BR-03 | no change | 40 |
| P-02154 | 36% | S16 | CR-01 | improved | 57 |
| P-02009 | 34% | S08 | CR-01 | improved | 64 |
| P-02054 | 33% | S01 | CR-01 | improved | 57 |
| P-02233 | 33% | S16 | CR-01 | improved | 66 |
| P-02151 | 28% | S04 | CR-01 | improved | 49 |
| P-02025 | 27% | S15 | CR-01 | improved | 61 |
| P-02395 | 27% | S12 | DT-01 | improved | 57 |
| P-02339 | 26% | S03 | DT-01 | improved | 50 |